Syndax Pharmaceuticals (SNDX) Gross Margin (2024 - 2026)

Syndax Pharmaceuticals' Gross Margin history runs 3 years deep, the most recent figure standing at 81.74% for Q1 2026.

• In Q1 2026, Gross Margin fell 1385.0% year-over-year to 81.74%; the TTM figure through Mar 2026 stood at 85.74% (down 96.0% YoY), while the FY2025 annual figure was 80.4%, up 122.0% from the prior year.
• Gross Margin was 81.74% for Q1 2026 at Syndax Pharmaceuticals, down from 86.04% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 100.0% in Q2 2024 to a low of 35.81% in Q4 2024.
• Historically, Gross Margin has averaged 84.72% across 3 years, with a median of 90.81% in 2025.
• Biggest YoY gain for Gross Margin was 5023 bps in 2025; the steepest drop was 1806 bps in 2025.
• A 3-year view of Gross Margin shows it stood at 35.81% in 2024, then jumped by 140 bps to 86.04% in 2025, then slipped by 5 bps to 81.74% in 2026.
• The last three Gross Margin figures came in at 81.74% (Q1 2026), 86.04% (Q4 2025), and 81.94% (Q3 2025), per Business Quant data.